Royalty Pharma (Royalty Pharma) Ending Cash Position : $477 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Ending Cash Position?

Royalty Pharma's Ending Cash Position for the quarter that ended in Dec. 2023 was $477 Mil.

Royalty Pharma's quarterly Ending Cash Position declined from Jun. 2023 ($2,173 Mil) to Sep. 2023 ($936 Mil) and declined from Sep. 2023 ($936 Mil) to Dec. 2023 ($477 Mil).

Royalty Pharma's annual Ending Cash Position increased from Dec. 2021 ($1,541 Mil) to Dec. 2022 ($1,711 Mil) but then declined from Dec. 2022 ($1,711 Mil) to Dec. 2023 ($477 Mil).

Royalty Pharma Ending Cash Position Historical Data

The historical data trend for Royalty Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Ending Cash Position Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

246.20

1,008.68

1,541.05

1,710.75

477.01

Royalty Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															1,710.75	1,975.69	2,173.08	936.45	477.01

Royalty Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Royalty Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1710.751	+	-1233.741
	=	477

Royalty Pharma's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	936.448	+	-459.438
	=	477

Royalty Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma (Royalty Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

RPRX:Mexico RPD:Germany RPD:Germany

Address

110 East 59th Street, FL 33, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Executives

Rory B Riggs	director	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Avara Management Ltd	10 percent owner	C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
Terrance P. Coyne	officer: EVP & CFO	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Pablo G. Legorreta	director, officer: CEO, Chairman of the Board	110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
George W. Lloyd	officer: EVP, Investments & GC	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Marshall Urist	officer: EVP, Research & Investments	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Mario Germano Giuliani	director, 10 percent owner	C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
James F. Reddoch	officer: EVP, Research & Investments	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Nogra Group Sicaf Sif Gg Strategic	10 percent owner	C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Nogra Group Sicaf - Sif S.a.	10 percent owner	18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Catherine M. Engelbert	director	110 NORTH CARPENTER STREET, CHICAGO IL 60607
Errol B Desouza	director	215 COLLEGE ROAD, PARAMUS NJ 07652
Henry A Fernandez	director	MSCI INC., 88 PINE STREET, NEW YORK NY 10005
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080